Hepatocellular Carcinoma Clinical Trial
Official title:
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
The goal of this first in human clinical trial is to test BI-1910 administered as single agent and in combination with pembrolizumab in subjects with advanced/metastatic solid tumors whose disease has progressed after standard therapy. The main questions it aims to answer are: - how safe and tolerable is BI-1910 - what is maximum tolerated or administrated dose - to determine recommended dose for further clinical trials Participants will receive infusions of BI-1910 alone or combination with pembrolizumab every 3 weeks.
Status | Recruiting |
Enrollment | 104 |
Est. completion date | November 7, 2028 |
Est. primary completion date | July 14, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Is willing and able to provide signed informed consent for the trial. 2. Is =18 years of age on the day of signing the informed consent form. 3. Has a histologically-confirmed advanced/metastatic solid tumor. 4. Has received standard of care and progressed or is intolerant of, or is not eligible to receive standard of care antineoplastic therapy. 5. Has at least 1 measurable disease lesion as defined by RECIST v1.1. 6. Must be willing to provide tumor biopsies as specified in the schedule of assessments 7. Has a life expectancy of =12 weeks. 8. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 9. Has adequate organ function as confirmed by laboratory values. Exclusion Criteria: 1. Needs doses of prednisolone >10 mg daily (or equipotent doses of other corticosteroids) while on the trial other than as premedication. 2. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. 3. Has known or suspected hypersensitivity to BI-1910 or pembrolizumab. 4. Has cardiac or renal amyloid light-chain amyloidosis. 5. Has received the following: 1. Chemotherapy or small molecule anti-cancer therapy products within 4 weeks, or 5 half-lives of the respective drug whichever is longer, of first dose of BI-1910. 2. Radiotherapy within 2 weeks of first dose of BI-1910. A 1-week washout is permitted for palliative radiation (=2 weeks of radiotherapy) for non-CNS disease. Subjects who have previously had radiation pneumonitis are not allowed. 3. Immunotherapy within 4 weeks prior to the first dose of BI-1910. 6. Has not recovered from AEs to at least Grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (v5.0 or higher). 7. Has had Grade =3 autoimmune manifestations of previous immune checkpoint inhibitor treatments (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4). 8. Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis. 9. Has an active, known, or suspected autoimmune disease. 10. Is a female subject and has the ability to become pregnant (or already pregnant or lactating/breastfeeding). However, those female subjects who have a negative serum or urine pregnancy test up to 72 hours prior to their first dose of study treatment and agree to use a highly effective method of birth control for 4 weeks before entering the trial, during the trial, and for 12 months after their last dose of study treatment are considered eligible. 11. Is a male subject with partner(s) of childbearing potential (unless he agrees to use a barrier method of contraception [condom plus spermicidal gel] with the female partner(s) who are using one highly effective method of contraception during the trial and for 12 months after completing treatment). 12. Has had major surgery from which the subject has not yet recovered. 13. Is at high medical risk because of nonmalignant systemic disease including severe active infections on treatment with antibiotics, antifungals, or antivirals other than the ones considered adequate for treatment of HBV. 14. Has presence of chronic graft versus host disease. 15. Has had an allogenic tissue/solid organ transplant. 16. Is positive for Human Immunodeficiency Virus (HIV). 17. Has history of chronic HBV or HCV infections. 18. Has a history of active tuberculosis (Bacillus tuberculosis). 19. Has received a live vaccine within 30 days before the first dose of study treatment. 20. Has uncontrolled or significant cardiovascular disease. 21. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the trial. 22. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator. 23. Is participating or planning to participate in another interventional clinical trial or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to first dose of study treatment. 24. Has a known additional malignancy of another type, with the exception of adequately treated cone-biopsied carcinoma in situ and basal or squamous cell carcinoma of the skin. Male subjects with asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for >1 year prior to start of study treatment are eligible. 25. Has a confirmed diagnosis of primary immunodeficiency or an acquired condition that leads to an immunodeficiency disorder or taking any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment. |
Country | Name | City | State |
---|---|---|---|
Denmark | Rigshospitalet | Copenhagen | |
Poland | Instytut Centrum Zdrowia Matki Polki | Lódz | |
Poland | Uniwersytecki Szpital Kliniczny | Poznan | |
Spain | Hospital HM Nou Delfos | Barcelona | |
Spain | HM Sanchinarro | Madrid | |
Spain | Hospital Fundacion Jimenez Diaz | Madrid | |
Spain | Hospital universitario Virgen del Rocio | Sevilla | |
Sweden | Karolinska University Hospital, Solna | Stockholm |
Lead Sponsor | Collaborator |
---|---|
BioInvent International AB | Merck Sharp & Dohme LLC |
Denmark, Poland, Spain, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence of adverse events (AEs) | AEs will be assessed by the investigators by severity and will be graded according to the NCI CTCAE v5.0 or higher and causality between AEs and the exposure to the study treatment. | From the start of the study treatment for up to 2 years and 90 days. | |
Primary | Occurrence of serious adverse events (SAEs) | SAEs will be assessed by the investigators by severity and will be graded according to the NCI CTCAE v5.0 or higher and causality between SAEs and the exposure to the study treatment | From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days | |
Primary | Frequency of AEs leading to discontinuation of study treatment | All adverse events leading to premature study treatment discontinuation will be analyzed descriptively utilizing corresponding MedDRA, System Organ Classes, and Preferred Terms. | From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days | |
Primary | Frequency of dose interruptions and dose reductions. | Study treatment modifications will be summarized in 2 categories: dose reduction and dose interruptions. The number and percentage of subjects who have any dose reduction or interruption and have at least 1 dose reduction or interruption will be summarized. Lastly, the primary reason for each form of study treatment modification will also be summarized. | From the start of the study treatment for up to 2 years | |
Primary | Changes from baseline in laboratory parameters | These include clinical laboratory assessments (hematology, clinical chemistry, urinalysis), additional CRP assessment, coagulation, thyroid, pregnancy, and viral serology assessments Safety laboratory results will be graded by NCI CTCAE v5.0 (or higher). If no grading exists, values will be classified into low/normal/high based on laboratory normal ranges. Each parameter will be presented by descriptive statistics at each visit, including change from baseline. | From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days | |
Primary | Changes from baseline in temperature (C or F) | Temperature (C or F) will be measured in a seated or supine position after 5 minutes' rest and will be summarized by descriptive statistics at each visit, including change from baseline. | From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days | |
Primary | Changes from baseline in Respiratory Rate (Breaths/Min) | Respiratory rate (breaths/min) will be measured in a seated or supine position after 5 minutes' rest and will be summarized by descriptive statistics at each visit, including change from baseline. | From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days | |
Primary | Changes from baseline in Blood Pressure (mmHg) | Systolic and diastolic blood pressure (mmHg) will be measured in a seated or supine position after 5 minutes' rest and will be summarized by descriptive statistics at each visit, including change from baseline. | From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days | |
Primary | Changes from baseline in O2 Saturation (%) | O2 Saturation (%) will be measured in a seated or supine position after 5 minutes' rest and will be summarized by descriptive statistics at each visit, including change from baseline. | From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days | |
Primary | Changes from baseline in weight | Weight (kg or lb) and body surface area (m2) will be collected at Screening and on each dose day before any study treatment is administered and will be summarized by descriptive statistics at each visit, including change from baseline. Height (cm or in) will be recorded at baseline only | From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days | |
Primary | Occurrence of dose limiting toxicities (DLTs) | All adverse events meeting the DLT criteria will be considered a DLT potentially related to the study treatment, regardless of Investigator/Sponsor causality assessment, excluding toxicities that are clearly related to disease progression or inter-current illness. DLTs will be considered by the safety monitoring committee for the purposes of dosing decisions. | During phase 1 Part A: from the first dose of BI-1910 for 21 days. During phase 1 part B: from the first dose of BI-1910 for 42 days. | |
Primary | identification of dose/dose range fulfilling favorable PK and pharmacodynamic profile, with acceptable safety | based on the totality of the efficacy, safety, PK, and pharmacodynamic endpoints | During phase 2a from screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days | |
Secondary | Maximum Concentration (Cmax) of BI-1910 | Maximum concentration (Cmax), obtained directly from the observed concentration-versus-time data will be determined. | From the start of the study treatment for up to 2 years and 90 days. | |
Secondary | Serum concentration-time curve [AUC] of BI-1910 | Area under the serum concentration-time curve will be determined. | From the start of the study treatment for up to 2 years and 90 days. | |
Secondary | Terminal half-life (t½) of BI-1910 | Terminal half-life will be determined, a minimum of 3 points will be used for estimation | From the start of the study treatment for up to 2 years and 90 days. | |
Secondary | Recommended dose range (RDR) | RDR is defined as the range between the minimal reproducibly active dose (MRAD), and the MTD or MAD. MRAD is the lowest dose level at which subjects experience tumor shrinkage and/or relevant PK/pharmacodynamic parameters indicate biological activity. | During phase 1 From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days | |
Secondary | Incidence and titer of antidrug antibodies (ADAs). | The detection and characterization of antibodies to BI-1910 will be performed. The samples collected will also be evaluated or BI-1910 serum concentration to enable interpretation of the antibody data. Antibodies may be further characterized and/or evaluated for their ability to neutralize the activity of the study treatments. | From the start of the study treatment for up to 2 years and 90 days. | |
Secondary | Objective response rate (ORR). | Objective response rate based on the best objective response, defined as achieving confirmed CR and/or PR measured by RECIST 1.1 and iRECIST, | During phase 2a from from the start of the study treatment for up to 2 years and 30 days | |
Secondary | Duration of response (DoR). | Defined as the time from the first assessment of PR or CR to the follow-up first assessment of PD measured by RECIST 1.1 and iRECIST. | During phase 2a from from the start of the study treatment for up to 2 years and 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |